This is a preview of subscription content, log in via an institution to check access.
References
Yamada N, Shigeta Y, Kaneko T, et al. Hypoglycemic effects and safety of a novel rapid-acting insulinotropic agent, KAD-1229, for NIDDM. Diabetes 1996 May; 45 Suppl. 2: 74
Mogami H, Shibata H, Nobusawa R, et al. Inhibition of ATP-sensitive K+ channel by a non-sulfonylurea compound KAD- 1229 in a pancreatic beta-cell line, MIN 6 cell. Eur J Pharmacol Mol Pharmacol 1994 Nov 15; 269: 293–8
Ohnota H, Koizumi T, Tsutsumi N, et al. Novel rapid- andshortacting hypoglycemic agent, a calcium(2S)-2-benzyl-3-(cishexahydro-2-isoindolinylcarbonyl) propionate (KAD-1229) that acts on the sulfonylurea receptor: comparison of effects between KAD-1229 and gliclazide. J Pharmacol Exp Ther 1994 May; 269: 489–95
Ohnota H, Kitamura T, Kinukawa M, et al. A rapid- and shortacting hypoglycemic agent KAD-1229 improves postprandial hyperglycemia and diabetic complications in streptozotocin-induced non-insulin-dependent diabetes mellitus rats. Jap J Pharmacol 1996 Aug; 71: 315–23
Komatsu H, Ohnota H, Koizumi T, et al. Pharmacological profile of a rapid- and short- acting hypoglycemic agent KAD-1229, a non-sulfonylurea drug. Naunyn-Schmiedebergs Arch Pharmacol 1998 No. 1; 358 Suppl. 1: 289
Rights and permissions
About this article
Cite this article
Mitiglinide. Drugs R&D 2, 114–115 (1999). https://doi.org/10.2165/00126839-199902020-00008
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-199902020-00008